# US 2004/0082031 A1 · Inflammatory inhibition factor fwa116

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082031 A1
- Document ID: US20040082031A1
- Status: Published application
- Kind: A1
- Application number: 10/469,625
- Filed: 2003-08-28
- Published: 2004-04-29
- Earliest claimed: 2001-02-28
- Inventors: Rutai Hui; Jingzhou Chen; Baohua Liu; Yuqing Liu; Yinhui Zhang
- Web page: https://patentgrep.com/patent/US20040082031A1

## CPC

- C07K 14/47: from mammals
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a polypeptide of the inflammatory inhibition factor Fwa116 and the polynucleotides encoding thereof. The present invention also relates to the method of producing polypeptide Fwa116 by recombinant technology and the antibody against it and an antagonist. The present invention also discloses pharmaceutical compositions containing the polypeptide Fwa116 and the use of the polypeptide in treating cardiovascular inflammatory arterosclerosis such as cerebral apoplexy, coronary heart disease, angina pectoris, myocardial infarction and controlling tumors. The present invention also provides the diagnosing and measuring method by detecting the mutation of nucleic acid sequence encoding Fwa116 or the content of the polypeptide Fwa116 and changes in levels of the auto-antibody of the gene product of Fwa116. The present inflammatory inhibition factor is human-derived.

## Claims

### Claim 1

An isolated polynucleotide comprising one member selected from the group consisting of:
(a) a polynucleotide, encoding the polypeptide of SEQ ID NO:2;
(b) a polynucleotide, being a naturally occurring variant of polynucleotide (a);
(c) a polynucleotide, hybridizing with (a) and having at least 85% of homology with (a).

### Claim 2 (depends on 1)

The polynucleotide of claim 1, wherein said polynucleotide is DNA.

### Claim 3 (depends on 1)

The polynucleotide of claim 1, wherein said polynucleotide is RNA.

### Claim 4 (depends on 1)

The polynucleotide of claim 1, wherein said polynucleotide is a genomic DNA.

### Claim 5 (depends on 1)

The polynucleotide of claim 1, wherein said polynucleotide has a sequence of SEQ ID NO:1.

### Claim 6 (depends on 1)

The polynucleotide of claim 1, wherein said polynucleotide comprises nucleotides 1002-2261 of SEQ ID NO:1.

### Claim 7 (depends on 2)

The polynucleotide of claim 2, encoding the polypeptide of SEQ ID NO:2.

### Claim 8 (depends on 2)

A vector comprising the DNA of claim 2.

### Claim 9 (depends on 8)

A host cell transformed or transfected with the vector of claim 8.

### Claim 10 (depends on 9)

A method for preparing a polypeptide, comprising the polypeptide encoded by said DNA as expressed in the host cell of claim 9.

### Claim 11

A polypeptide comprising one member selected by the group consisting of:
(a) a polypeptide, having the deduced amino acid sequence of SEQ ID NO:2;
(b) a polypeptide, being an active fragment, analogue or derivative of (a);
(c) a polypeptide, having at least 85% of homology with the amino acid sequence of SEQ ID NO:2.

### Claim 12 (depends on 11)

An antibody against the polypeptide of claim 11.

### Claim 13 (depends on 11)

A compound inhibiting the activation of the polypeptide of claim 11.

### Claim 14 (depends on 11)

A pharmaceutical composition comprising an effective amount of the polypeptide of claim 11 or the active fragment thereof and one or more pharmacologically acceptable carriers or excipients.

### Claim 15 (depends on 11)

Use of the polypeptide of claim 11 for preparing the pharmaceutical composition in the treatment of cardiovascular inflammatory arteroscierosis and tumors.

### Claim 16 (depends on 15)

The use of claim 15, wherein said cardiovascular inflammatory arterosclerosis includes cerebral apoplexy, coronary heart disease, angina pectoris and myocardial infarction.

### Claim 17 (depends on 11)

A method for treatment of a patient in need of Fwa116 comprising administration of a therapeutically effective amount of the-polypeptide of claim 11 to the patient.

### Claim 18 (depends on 17)

The method of claim 17 comprising administration of the DNA encoding said polypeptide to the patient and expression of said polypeptide in the body of the patient.

### Claim 19 (depends on 1)

A method for diagnosis of a disease or susceptibility of the disease comprising determination of the mutation of the polynucleotide of claim 1.

### Claim 20 (depends on 11)

A method for diagnosis comprising analysis of whether the polypeptide of claim 11 is present in the sample from the host cell or not.
